These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. Aires CC; van Cruchten A; Ijlst L; de Almeida IT; Duran M; Wanders RJ; Silva MF J Hepatol; 2011 Aug; 55(2):426-34. PubMed ID: 21147182 [TBL] [Abstract][Full Text] [Related]
7. 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy. Inoue K; Suzuki E; Takahashi T; Yamamoto Y; Yazawa R; Takahashi Y; Imai K; Miyakawa K; Inoue Y; Tsuji D; Hayashi H; Itoh K Epilepsy Res; 2014 Aug; 108(6):1046-51. PubMed ID: 24888247 [TBL] [Abstract][Full Text] [Related]
8. L-Arginine in the treatment of valproate overdose - five clinical cases. Schrettl V; Felgenhauer N; Rabe C; Fernando M; Eyer F Clin Toxicol (Phila); 2017 Apr; 55(4):260-266. PubMed ID: 28152637 [TBL] [Abstract][Full Text] [Related]
9. [Cerebral edema with hyperammonemia in valpromide poisoning. Manifestation in an adult, of a partial deficit in type I carbamylphosphate synthetase]. Bourrier P; Varache N; Alquier P; Rabier D; Kamoun P; Lorre G; Alhayek G Presse Med; 1988 Nov; 17(39):2063-6. PubMed ID: 2974563 [TBL] [Abstract][Full Text] [Related]
10. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. Ohtani Y; Endo F; Matsuda I J Pediatr; 1982 Nov; 101(5):782-5. PubMed ID: 6813444 [TBL] [Abstract][Full Text] [Related]
11. [Hyperammonemia in valproate therapy in children and adolescents]. Laub MC Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461 [TBL] [Abstract][Full Text] [Related]
13. Valproate use associated with persistent hyperammonemia and mitochondrial injury in a child with Down's syndrome. Kane RE; Kotagel S; Bacon BR; Vogler CA J Pediatr Gastroenterol Nutr; 1992 Feb; 14(2):223-7. PubMed ID: 1534366 [TBL] [Abstract][Full Text] [Related]
14. Renal handling of carnitine in children with carnitine deficiency and hyperammonemia associated with valproate therapy. Matsuda I; Ohtani Y; Ninomiya N J Pediatr; 1986 Jul; 109(1):131-4. PubMed ID: 3088240 [TBL] [Abstract][Full Text] [Related]
15. Heterozygote ornithine transcarbamylase deficiency presenting as symptomatic hyperammonemia during initiation of valproate therapy. Honeycutt D; Callahan K; Rutledge L; Evans B Neurology; 1992 Mar; 42(3 Pt 1):666-8. PubMed ID: 1549234 [TBL] [Abstract][Full Text] [Related]
17. Asymptomatic hyperammonemia in children treated with valproic acid. Altunbaşak S; Baytok V; Tasouji M; Hergüner O; Burgut R; Kayrin L J Child Neurol; 1997 Oct; 12(7):461-3. PubMed ID: 9373804 [No Abstract] [Full Text] [Related]
18. Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient. Kulick SK; Kramer DA Ann Emerg Med; 1993 Mar; 22(3):610-2. PubMed ID: 8192712 [TBL] [Abstract][Full Text] [Related]
19. Acute hyperammonemic coma with chronic valproic acid therapy. Cuturic M; Abramson RK Ann Pharmacother; 2005 Dec; 39(12):2119-23. PubMed ID: 16288075 [TBL] [Abstract][Full Text] [Related]